Phase I/II Study to Determine the Maximum Tolerated Dose and Activity of the Combination of Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Romidepsin (Primary)
- Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms RomiCar
- 09 Jun 2018 Planned End Date changed from 13 Jul 2020 to 1 Feb 2021.
- 09 Jun 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2019.
- 04 Aug 2016 Planned End Date changed from 1 Feb 2016 to 13 Jul 2020.